Novavax Inc

NASDAQ:NVAX USA Biotechnology
Market Cap
$1.73 Billion
Market Cap Rank
#5851 Global
#3389 in USA
Share Price
$10.64
Change (1 day)
+5.56%
52-Week Range
$5.43 - $11.19
All Time High
$319.93
Categories
Companies in USA Biotechnology
About

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more

Novavax Inc (NVAX) - Net Assets

Latest net assets as of December 2025: $-127.75 Million USD

Based on the latest financial reports, Novavax Inc (NVAX) has net assets worth $-127.75 Million USD as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.18 Billion) and total liabilities ($1.30 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $-127.75 Million
% of Total Assets -10.86%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility 238.42

Novavax Inc - Net Assets Trend (1996–2025)

This chart illustrates how Novavax Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Novavax Inc (1996–2025)

The table below shows the annual net assets of Novavax Inc from 1996 to 2025.

Year Net Assets Change
2025-12-31 $-127.75 Million +79.52%
2024-12-31 $-623.84 Million +12.98%
2023-12-31 $-716.93 Million -13.07%
2022-12-31 $-634.08 Million -80.30%
2021-12-31 $-351.67 Million -156.07%
2020-12-31 $627.21 Million +437.18%
2019-12-31 $-186.02 Million -10.77%
2018-12-31 $-167.94 Million -65.08%
2017-12-31 $-101.73 Million -1734.33%
2016-12-31 $-5.55 Million -101.89%
2015-12-31 $292.67 Million +27.46%
2014-12-31 $229.62 Million +12.98%
2013-12-31 $203.23 Million +153.28%
2012-12-31 $80.24 Million +49.01%
2011-12-31 $53.85 Million -8.81%
2010-12-31 $59.05 Million -20.70%
2009-12-31 $74.47 Million +63.70%
2008-12-31 $45.49 Million -27.87%
2007-12-31 $63.06 Million -32.91%
2006-12-31 $94.00 Million +89.32%
2005-12-31 $49.65 Million +49.19%
2004-12-31 $33.28 Million -7.41%
2003-12-31 $35.94 Million +345.24%
2002-12-31 $8.07 Million -70.64%
2001-12-31 $27.49 Million -13.61%
2000-12-31 $31.82 Million +1036.57%
1999-12-31 $2.80 Million -6.67%
1998-12-31 $3.00 Million -53.85%
1997-12-31 $6.50 Million +27.45%
1996-12-31 $5.10 Million --

Equity Component Analysis

This analysis shows how different components contribute to Novavax Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 454134800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $1.65 Million %
Other Comprehensive Income $2.01 Million %
Other Components $4.44 Billion %
Total Equity $-127.75 Million 100.00%

Novavax Inc Competitors by Market Cap

The table below lists competitors of Novavax Inc ranked by their market capitalization.

Company Market Cap
Agios Pharmaceuticals, Inc.
LSE:0HB0
 		$1.49 Billion
Nanjing Yunhai Special Metals Co Ltd
SHE:002182
 		$1.49 Billion
REA Group Limited
PINK:RPGRY
 		$1.49 Billion
RED CAT HDGS INC.DL -001
F:BQ73
 		$1.49 Billion
Sejahteraraya Anugrahjaya Tbk
JK:SRAJ
 		$1.49 Billion
NRW Holdings Ltd
AU:NWH
 		$1.49 Billion
NAPCO Security Technologies Inc
NASDAQ:NSSC
 		$1.49 Billion
Ningxia Jiaze Renewables Corp
SHG:601619
 		$1.49 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Novavax Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -623,841,000 to -127,753,000, a change of 496,088,000.
  • Net income of 440,302,000 contributed positively to equity growth.
  • Share repurchases of 4,798,000 reduced equity.
  • Other comprehensive income increased equity by 24,569,000.
  • Other factors increased equity by 36,015,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $440.30 Million +344.65%
Share Repurchases $4.80 Million -3.76%
Other Comprehensive Income $24.57 Million +19.23%
Other Changes $36.02 Million +28.19%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares Novavax Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1996-12-31 $10.07 $10.64 x
1997-12-31 $11.14 $10.64 x
1998-12-31 $4.83 $10.64 x
1999-12-31 $3.86 $10.64 x
2000-12-31 $33.47 $10.64 x
2001-12-31 $24.25 $10.64 x
2002-12-31 $6.61 $10.64 x
2003-12-31 $24.08 $10.64 x
2004-12-31 $18.03 $10.64 x
2005-12-31 $23.22 $10.64 x
2006-12-31 $32.05 $10.64 x
2007-12-31 $20.64 $10.64 x
2008-12-31 $13.34 $10.64 x
2009-12-31 $17.41 $10.64 x
2010-12-31 $11.27 $10.64 x
2011-12-31 $9.48 $10.64 x
2012-12-31 $12.18 $10.64 x
2013-12-31 $23.96 $10.64 x
2014-12-31 $20.33 $10.64 x
2015-12-31 $22.32 $10.64 x
2016-12-31 $-0.41 $10.64 x
2017-12-31 $-6.95 $10.64 x
2018-12-31 $-9.08 $10.64 x
2019-12-31 $-7.72 $10.64 x
2020-12-31 $10.90 $10.64 x
2021-12-31 $-4.73 $10.64 x
2022-12-31 $-8.11 $10.64 x
2023-12-31 $-7.11 $10.64 x
2024-12-31 $-4.10 $10.64 x
2025-12-31 $-0.74 $10.64 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Novavax Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 39.19%
  • • Asset Turnover: 0.95x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-50.90%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 -107.84% -5500.00% 0.02x 1.12x $-6.01 Million
1997 -69.23% -900.00% 0.07x 1.05x $-5.15 Million
1998 -160.00% -685.71% 0.18x 1.27x $-5.10 Million
1999 -160.71% -375.00% 0.27x 1.61x $-4.78 Million
2000 -38.31% -492.57% 0.04x 1.78x $-15.37 Million
2001 -35.45% -40.49% 0.36x 2.44x $-12.49 Million
2002 -281.15% -151.26% 0.26x 7.12x $-23.50 Million
2003 -48.06% -146.57% 0.14x 2.34x $-20.87 Million
2004 -77.88% -313.80% 0.11x 2.34x $-29.25 Million
2005 -22.50% -151.25% 0.09x 1.70x $-16.14 Million
2006 -24.54% -492.59% 0.04x 1.30x $-32.47 Million
2007 -55.13% -2297.75% 0.02x 1.45x $-41.07 Million
2008 -79.25% -3388.06% 0.01x 1.68x $-40.60 Million
2009 -51.53% -11807.38% 0.00x 1.15x $-45.82 Million
2010 -60.47% -10410.50% 0.00x 1.27x $-41.61 Million
2011 -35.96% -131.84% 0.22x 1.24x $-24.75 Million
2012 -35.53% -129.13% 0.22x 1.28x $-36.53 Million
2013 -25.58% -248.54% 0.09x 1.16x $-72.31 Million
2014 -36.12% -270.55% 0.11x 1.20x $-105.91 Million
2015 -53.62% -432.93% 0.09x 1.32x $-186.20 Million
2016 0.00% -1823.53% 0.04x 0.00x $-279.41 Million
2017 0.00% -589.46% 0.10x 0.00x $-173.60 Million
2018 0.00% -538.81% 0.16x 0.00x $-167.95 Million
2019 0.00% -697.15% 0.11x 0.00x $-111.50 Million
2020 -68.16% -89.89% 0.30x 2.52x $-490.23 Million
2021 0.00% -152.12% 0.44x 0.00x $-1.71 Billion
2022 0.00% -41.15% 0.71x 0.00x $-594.53 Million
2023 0.00% -97.97% 0.31x 0.00x $-473.37 Million
2024 0.00% -27.49% 0.44x 0.00x $-125.11 Million
2025 0.00% 39.19% 0.95x 0.00x $453.08 Million

Industry Comparison

This section compares Novavax Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $59,082,939
  • Average return on equity (ROE) among peers: -341.19%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Novavax Inc (NVAX) $-127.75 Million -107.84% N/A $1.49 Billion
Aadi Bioscience Inc (AADI) $-124.24K 0.00% 0.00x $17.03 Million
America Great Health (AAGH) $-992.37K 0.00% 0.00x $2.12 Million
Ascentage Pharma Group International (AAPG) $70.63 Million -1310.51% 34.40x $2.25 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD) $-27.92 Million 0.00% 0.00x $59.18 Million
ABIVAX Société Anonyme (AAVXF) $196.01 Million -75.37% 0.67x $377.86 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $738.02 Million
Abeona Therapeutics Inc (ABEO) $489.00K -1919.02% 38.85x $202.79 Million
Acumen Pharmaceuticals Inc (ABOS) $188.78 Million -22.70% 0.04x $108.65 Million
Abpro Holdings, Inc. (ABP) $-22.46 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $176.18 Million -62.76% 0.23x $345.85 Million